Mar. 3 at 1:00 PM
$TLPH As you know, Niyad is a powder form of Nafamostat. It has many advantages over Nafamostat. The huge amounts of good data of Nafamostat are very helpful, but they still need to prove that converting it into powder did not create any problems.
I'm thinking that TLPH was deliberately pushed down to near
$0.75 in February to allow the two funds that bought at the 17 enrollees mark to buy at the 35 enrollees mark. I think that the day it went down to near
$0.75 is the day they bought (directly from the company, not from the open market). I don't remember exactly when that happened (and I don't care to look it up), but it was about mid-February, which means the 35 enrollees must have been done a few days before that. Obviously, all this is wishful thinking on my part, but it's not totally nonsensical.
Even if I'm right, it's still disappointing that it took them till early February to be done with 35 enrollees. At this rate, they won't be done with phase III till very late this year.
